Current US cash prices for weight-loss GLP-1 medications, by dose, copied from the manufacturers' own pages. List prices and diabetes versions are included for comparison.
Last updated: · Prices checked daily against the sources listed for each medication.
Quick answer
Without insurance, manufacturer self-pay prices for FDA-approved weight-loss GLP-1s start at $149 a month (Wegovy pill and Foundayo, lowest strengths) and go up with the dose: most Zepbound strengths are $449 a month with on-time refills ($499 to $699 otherwise). List prices, which are not what most cash buyers pay, run from $499 to $1,349.02 per fill or package.
Prices at a glance
Self-pay = the manufacturer's cash price per month. List price = wholesale acquisition cost before rebates. Scroll sideways on small screens.
Each figure below is copied from the linked manufacturer page. Offers have conditions, such as refill timing or end dates, which are noted.
Wegovy pill
semaglutide tablets · Novo Nordisk · Daily tablet
FDA-approved for
Chronic weight management (see prescribing information for full indications)
List price
$1,349.02 per package of 30 tablets (all strengths)
Self-pay
Strength
Price
1.5 mg
$149
4 mg
$199
9 mg
$299
25 mg
$299
per month (30 tablets), NovoCare Pharmacy
With insurance
As little as $25/month with commercial coverage (max savings $100/month); government beneficiaries excluded. Eligible Medicare Part D enrollees: $50/month copay through the Medicare GLP-1 Bridge.
Good to know
Novo Nordisk says the list price of Wegovy 25 mg tablets will drop to $675 from January 1, 2027.
Chronic weight management (see prescribing information for full indications)
List price
$1,349.02 per package (all strengths, including Wegovy HD 7.2 mg)
Self-pay
Strength
Price
0.25 mg or 0.5 mg, first 2 monthly fills (new patients, through Dec 31, 2026)
$199
0.25 mg to 2.4 mg (standard price)
$349
Wegovy HD 7.2 mg
$399
per month (1 box of 4 pens), NovoCare Pharmacy
With insurance
As little as $25/month with commercial coverage (max savings $100/month); government beneficiaries excluded. Eligible Medicare Part D enrollees: $50/month copay through the Medicare GLP-1 Bridge.
Good to know
Novo Nordisk says the list price of Wegovy 2.4 mg injection will drop to $675 from January 1, 2027. Self-pay prices are separate from list price.
tirzepatide injection · Eli Lilly · Weekly multi-dose pen
FDA-approved for
Chronic weight management; moderate to severe obstructive sleep apnea in adults with obesity
List price
$499 to $1,086.37 per fill (range across Zepbound products)
Self-pay
Strength
Price
2.5 mg
$299
5 mg
$399
7.5 mg
$449 with on-time refill; otherwise $499
10 mg, 12.5 mg, 15 mg
$449 with on-time refill; otherwise $699
per month (28 days; 1 KwikPen), LillyDirect or with the Zepbound self-pay savings card at retail pharmacies
With insurance
Eligible Medicare Part D enrollees: $50/month copay through the Medicare GLP-1 Bridge (KwikPen). For commercial coverage, see the single-dose pen note.
Good to know
$449 requires the Zepbound Journey Program: refill within 45 days of the previous delivery. Pen needles are bought separately. Self-pay savings card valid through Dec 31, 2026.
tirzepatide injection · Eli Lilly · Weekly vial (draw up with syringe)
FDA-approved for
Chronic weight management; moderate to severe obstructive sleep apnea in adults with obesity
List price
$499 to $1,086.37 per fill (range across Zepbound products)
Self-pay
Strength
Price
2.5 mg
$299
5 mg
$399
7.5 mg
$449 with on-time refill; otherwise $499
10 mg, 12.5 mg, 15 mg
$449 with on-time refill; otherwise $699
per month (28 days; 4 vials), LillyDirect only
With insurance
Vials are a self-pay option. With commercial coverage, Lilly's savings card lets you pay as low as $25 for a 1- or 3-month supply of the Zepbound single-dose pen (subject to monthly and annual limits; government beneficiaries excluded).
Good to know
$449 requires the Zepbound Journey Program: refill within 45 days. Needles and syringes are bought separately.
Chronic weight management (FDA approved April 1, 2026)
List price
$649.00 per 30-day supply
Self-pay
Strength
Price
0.8 mg
$149
2.5 mg
$149 through Dec 31, 2026 (regular $199)
5.5 mg
$199 through Dec 31, 2026 (regular $299)
9 mg
$299
14.5 mg, 17.2 mg
$299 with on-time refill; otherwise $349
per month (30 days), LillyDirect or with the Foundayo self-pay savings card
With insurance
As little as $25/month with commercial coverage (max savings $100/month, $1,000/year); government beneficiaries excluded. Eligible Medicare Part D enrollees: $50/month through the Medicare GLP-1 Bridge.
Good to know
$299 for 14.5 mg and 17.2 mg requires a refill within 45 days of the previous delivery.
Chronic weight management in adults and children 12+ (see prescribing information)
List price
$1,349.02 per package of 5 pens
Self-pay
Not published (no NovoCare Pharmacy self-pay price)
With insurance
Coverage depends on your plan.
Good to know
Novo Nordisk is discontinuing Saxenda, with last shipments to wholesalers in late January 2027. The company says this is not due to safety or quality concerns.
tirzepatide injection · Eli Lilly · Weekly single-dose pen
FDA-approved for
Type 2 diabetes (not approved for weight management)
List price
$1,112.16 per fill
Self-pay
Strength
Price
All doses (2.5 mg to 15 mg)
$499
per month, LillyDirect
With insurance
As little as $25 for a 1- to 3-month fill with commercial coverage (max savings $150/month, $1,950/year); $499/month if your commercial plan does not cover Mounjaro. Government beneficiaries excluded.
Good to know
Not part of the Medicare GLP-1 Bridge, which covers weight-management drugs only.
Compounded drugs are not FDA-approved. Compounded semaglutide, tirzepatide and liraglutide are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. There is no official price list; prices are set by each telehealth company or pharmacy.
A peer-reviewed study of websites selling compounded GLP-1s (data collected July–September 2024) found these median first-month prices, including discounts.
From July 1, 2026 to December 31, 2027, eligible Medicare Part D enrollees can get Wegovy (injection and tablets), the Zepbound KwikPen and Foundayo for weight management for a $50 monthly copay. Source: CMS.
Methodology
Sources. We only use official pages: manufacturer pricing and savings pages (NovoCare, novopricing.com, LillyDirect, pricinginfo.lilly.com and each brand's savings page), manufacturer press releases, and CMS. Each row links the exact pages used.
What we record. The manufacturer's self-pay (cash) price for a one-month supply at each strength, and the published list price (wholesale acquisition cost). Retail pharmacy, discount-card and telehealth prices vary and are not tracked.
No estimates. If an official price is not published, we say "Not published" rather than estimate one.
Daily check. Every source URL is re-checked every 24 hours. When a figure changes, we update the row, its "last verified" date and the changelog.
What a month means. Manufacturers define it differently: 28 days for Zepbound, 30 tablets for Wegovy and Ozempic pills, and one box or pen for the injections. Taxes and fees may apply.
Price is only one part of choosing a treatment. Which medicine and dose, if any, is right for you is a decision for you and a licensed clinician.
Changelog
: Tracker launched. All prices checked against manufacturer and CMS pages.
Cite or embed this page
You are welcome to cite these figures with a link to this page. The raw data is available as JSON.
Frequently asked questions
What is the cheapest FDA-approved GLP-1 for weight loss without insurance?
As of November 3, 2026, the lowest manufacturer self-pay price for a GLP-1 approved for weight management is $149 a month, for the Wegovy pill and the Foundayo at their lowest strengths. Prices rise at higher strengths, so the dose your clinician prescribes decides what you pay. See the dose-by-dose tables above.
Why is the list price so much higher than the self-pay price?
The list price (wholesale acquisition cost) is what the manufacturer charges wholesalers before rebates and discounts. Self-pay prices are separate cash offers sold through the manufacturer's own pharmacy or savings programs. Most people paying cash pay the self-pay price, not the list price.
Are compounded GLP-1s cheaper?
Sometimes, but they are not FDA-approved and there is no official price list. A 2024 study of compounding websites found a median first-month price of $231 for compounded semaglutide and $330 for compounded tirzepatide. Several FDA-approved self-pay prices are now in a similar range. See the compounded section above.
Does Medicare pay for GLP-1s for weight loss?
From July 1, 2026 to December 31, 2027, eligible Medicare Part D enrollees can get Wegovy (injection and tablets), the Zepbound KwikPen and Foundayo for weight management for a $50 monthly copay. Eligibility rules apply.
Why are Ozempic and Mounjaro on the list?
They share active ingredients with Wegovy (semaglutide) and Zepbound (tirzepatide), so people often compare their prices. Ozempic and Mounjaro are FDA-approved for type 2 diabetes, not for weight management.
How often is this page updated?
Every source on this page is re-checked daily against the manufacturer and government pages listed for each medication. When a price changes, we update the table and add an entry to the changelog with the date.
Your first 90 days on one printable guide: doctor-visit questions, a cost and coverage worksheet, a side-effect playbook and 12 weeks of trackers. Plus new evidence-based guides by email.
Cookies and privacy
We'd like to use Google Analytics cookies to count visits and see which pages are useful. They are off unless you accept, and you can change your choice anytime via "Cookie settings" at the bottom of every page. We don't use advertising cookies. Privacy policy.